New pill targets Hard-to-Treat cancers with MAPK gene flaw

NCT ID NCT05886920

Recruiting now Disease control Sponsor: D3 Bio (Wuxi) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026

Summary

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) in people with non-small cell lung cancer. The main goals are to check safety and find the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH MAPK PATHWAY MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

D3 Bio Investigative Site
RECRUITING

Detroit, Michigan, 48202, United States
D3 Bio Investigative Site
COMPLETED

New York, New York, 10029, United States
D3 Bio Investigative Site
RECRUITING

Nashville, Tennessee, 37203, United States
D3 Bio Investigative Site
COMPLETED

Blacktown, New South Wales, 2148, Australia
D3 Bio Investigative Site
RECRUITING

Macquarie Park, New South Wales, 2109, Australia
D3 Bio Investigative Site
COMPLETED

Bedford Park, South Australia, 5042, Australia
D3 Bio Investigative Site
COMPLETED

Nedlands, Western Australia, 6009, Australia
D3 Bio Investigative Site
RECRUITING

Beijing, Beijing Municipality, 100142, China
D3 Bio Investigative Site
RECRUITING

Guangzhou, Guangdong, 510080, China
D3 Bio Investigative Site
COMPLETED

Harbin, Heilong Jiang, 150081, China
D3 Bio Investigative Site
RECRUITING

Wuhan, Hubei, 430079, China
D3 Bio Investigative Site
ACTIVE_NOT_RECRUITING

Shanghai, Shanghai Municipality, 201801, China
D3 Bio Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310009, China
D3 Bio Investigative Site
RECRUITING

Seoul, 03722, South Korea

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

D3S-002 (oral tablet) and D3S-001 (oral capsule)

What this could lead to

If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific MAPK pathway mutations.

What could go wrong

This is an early first-in-human study with only 67 participants, so safety and effectiveness are not yet known. Many early-stage cancer drugs do not advance to later trials.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS WITH MAPK PATHWAY MUTATIONS